Agilent Technologies, Inc. · NYSE:A
Agilent Technologies — Q4 2019 Earnings Presentation
8 slides from Agilent Technologies's earnings presentation, November 2019
Slide 1: Agilent Technologies Q4'19 Results Presentation
Agilent Technologies Q4'19 Results Presentation
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements (including, without limitation, information and future guidance on the company’s goals, priorities, revenue, revenue growth, earnings per share, operating margin, operating cash flow, capital expenditures, capital allocation, growth o
Slide 3: Agilent Results Q4'19
Agilent Results Q4'19 Scale and leading technology across Analytical Laboratories and Clinical & Dx markets Q4'19 Financial Metrics FY19 Highlights • Revenues: $1.37B, +3.6% y/y • Revenue: Core revenue growth of 5.0%. Double-digit core(1)(2),+5.7% reported (+3.6% M&A, -1.5% core growth delivered by
Slide 4: Life Sciences & Applied Markets Group (LSAG)
Life Sciences & Applied Markets Group (LSAG) • Q4 Core Revenue performance reflected Instrumentation and Informatics for Analytical Laboratories continued strength in Environmental & Forensics markets offset by weakness as expected in China Food, slowing Chemical & Energy, and a difficult Pharma com
Slide 5: Agilent Cross Lab Group (ACG)
Agilent Cross Lab Group (ACG) • Continued strong revenue performance across Analytical Laboratory Consumables and Services both services and consumables. Broad growth across major markets and regions. • ACG grew in the mid-teens in China, leveraging Agilent’s large instrument installed base and expa
Slide 6: Diagnostics and Genomics Group (DGG)
Diagnostics and Genomics Group (DGG) • In the quarter DGG crossed the $1B revenue Pathology, Genomics, and threshold for the year and now represents 20 Nucleic Acid Manufacturing percent of Agilent’s business. • Healthy core revenue growth driven by solid growth in Pathology and Companion Dx, and on
Slide 7: Growth in a $52B Market – Q4'19 Results by End Market
Growth in a $52B Market – Q4'19 Results by End Market Strong Gains in broader Pharma, Diagnostics and Environmental Markets Analytical Laboratory End Markets Q4'19 revenues: +3% y/y on core(2) basis Pharma & Biotech: Up 7% with strength in Bio-Pharma, Chemical Services, Chemistries and Consumabl
Slide 8: Q1'20 and FY20 Guidance and Forward-looking Considerations
Q1’20 and FY20 Guidance and Forward-looking Considerations Based on October 31, 2019 Exchange Rates Q1’20 Guidance (1) FY20 Guidance (1) Low End High End Low End High End Net Revenue ($M) $1,340 $1,355 Net Revenue ($M) $5,500 $5,550 Y/Y Core Revenue Growth (2) 2.5% 3.5% Y/Y Core Revenue Growth (2) 4